Related Experiment Video
Updated: Mar 14, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
In silico structural characterization of protein targets for drug development against Trypanosoma cruzi
Carlyle Ribeiro Lima1,2, Nicolas Carels3, Ana Carolina Ramos Guimaraes4
1Molécules Thérapeutiques in silico, Université Paris Diderot, INSERM UMR-S 973, Sorbonne Paris Cité, 75013, Paris, France.
Abstract:
Trypanosoma cruzi is the protozoan pathogen responsible for Chagas disease, which is a major public health problem in tropical and subtropical regions of developing countries and particularly in Brazil. Despite many studies, there is no efficient treatment against Chagas disease, and the search for new therapeutic targets specific to T. cruzi is critical for drug development. Here, we have revisited 41 protein sequences proposed by the analogous enzyme pipeline, and found that it is possible to provide structures for T. cruzi sequences with clear homologs or analogs in H. sapiens and likely associated with trypanothione reductase, cysteine synthase, and ATPase functions, and structures for sequences specific to T. cruzi and absent in H. sapiens associated with 2,4-dienoyl-CoA reductase, and leishmanolysin activities. The implications of our structures refined by atomistic molecular dynamics (monomer or dimer states) in their in vitro environments (aqueous solution or membrane bilayers) are discussed for drug development and suggest that all protein targets, except cysteine synthase, merit further investigation.
Insights
Researchers identified potential drug targets for Chagas disease by analyzing Trypanosoma cruzi proteins. Structures of specific T. cruzi proteins, absent in humans, offer promising avenues for developing new treatments against this neglected tropical disease.
Area of Science:
- Parasitology
- Drug Discovery
- Structural Biology
Background:
- Chagas disease, caused by Trypanosoma cruzi, is a significant public health issue in tropical regions.
- Current treatments for Chagas disease are inefficient, necessitating the identification of novel therapeutic targets.
Purpose of the Study:
- To analyze protein sequences of Trypanosoma cruzi for potential drug targets.
- To identify T. cruzi-specific proteins absent in humans as potential therapeutic targets.
Main Methods:
- Revisiting 41 protein sequences from the analogous enzyme pipeline.
- Determining protein structures using atomistic molecular dynamics simulations.
- Evaluating protein behavior in aqueous solutions and membrane bilayers.
Main Results:
- Identified structures for T. cruzi proteins with human homologs (trypanothione reductase, cysteine synthase, ATPase).
- Identified structures for T. cruzi-specific proteins absent in humans (2,4-dienoyl-CoA reductase, leishmanolysin).
- Structural analysis suggests potential for drug development against T. cruzi.
Conclusions:
- Protein targets like 2,4-dienoyl-CoA reductase and leishmanolysin are promising for Chagas disease drug development.
- Cysteine synthase was excluded as a target, while others warrant further investigation.
- Structural insights aid in designing targeted therapies against Trypanosoma cruzi.
More Related Videos
06:13Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
Published on: July 31, 2019
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
